Use of thrombin generation assay to personalize treatment of breakthrough bleeds in a patient with hemophilia and inhibitors receiving prophylaxis with emicizumab

Yesim Dargaud, Anne Lienhart, Maissaa Janbain, Sandra LeQuellec, Nathalie Enjolras, and Claude Negrier

Disclosures: Conflicts of Interests Y Dargaud received grants/research support from Bayer, Baxter, Baxalta, Novo Nordisk, CSL Behring, LFB, Pfizer, LeoPharma, Octapharma and Stago; and honoraria from Bayer, Baxter, Novo Nordisk, CSL Behring, Sobi, Shire and Octapharma. A Lienhart received honoraria from Novo Nordisk, CSL Behring and Sobi. M Janbain received consultant honoraria from Bayer, Genentech, CSL Behring, Shire, Alnylam and HEMA biologics. S LeQuellec received grants/research support from CSL Behring and honoraria from Shire and LFB Biomedicaments. N Enjolras received research grant from Pfizer. SLQ received research grant from CSL Behring, consultant honoraria from Novo Nordisk, Shire and LFB. C Negrier received honoraria from Bayer, Baxter, Baxalta, Novo Nordisk, CSL Behring, LFB, Pfizer, LeoPharma, Octapharma, Shire, Sobi, Roche and Stago.

Contributions: YD designed the protocol, performed thrombin generation tests, analysed/interpreted data and wrote the manuscript; AL followed-up the patient and managed haemophilia treatments; MJ participated to data analysis and edited the manuscript. NE participated to data analysis and edited the manuscript; SLQ and CN participated to the patient’s clinical follow-up. All authors approved the manuscript.